Original Publication Date: 1 June, 2015
Publication / Source: Future Oncology
Authors: Leigh Ellis
Emergence of aggressive prostate cancer (PCa) phenotypes resistant to current available therapies is a significant clinical problem, and novel therapeutic strategies are urgently required. Androgen receptor (AR) action is a key mediator underlying development and progression of PCa. For this reason, androgen deprivation therapy has been a primary standard of care for men for over 70 years with symptomatic, advanced PCa . Unfortunately, ensuing resistance to therapy is inevitable, and men will eventually develop castration-resistant PCa (CRPC).